Financials

  • Market Capitalization 7.95 B
  • Employee 315
  • Founded 2018
  • CEO N/A
  • Website www.immunovant.com
  • Headquarter Delaware, United States
  • FIGI BBG00P5MC0Q8
  • Industry Biotecnologia
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-8.97
Rapporto prezzo/fatturato

Related tickers

#NomePrezzo24h %7d %1M %1Y %Valore di MercatoUltimi 7 Giorni
1021
IBRX
ImmunityBio, Inc. - Common Stock
7.93 USD+1.80%-7.25%+9.38%+171.58%8.31 B USD
1038
PCVX
Vaxcyte, Inc. - Common Stock
56.05 USD-1.72%-5.43%+17.48%+32.51%8.09 B USD
1060
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
62.65 USD+2.81%-3.03%+21.06%+58.03%7.83 B USD
1085
RYTM
Rhythm Pharmaceuticals, Inc. - Common Stock
108.96 USD+1.37%-4.72%+17.16%-1.22%7.47 B USD

Notizie